• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

NYU Researchers Find Blood Test Can Measure Effectiveness of Melanoma Treatments

Article

Researchers from the NYU School of Medicine and Perlmutter Cancer Center have determined that blood tests that track the amount of tumor DNA—after just 1 month of treatment—detect how well treatment is working in patients with skin cancer.

Researchers from the NYU School of Medicine and Perlmutter Cancer Center have determined that blood tests that track the amount of tumor DNA—after just 1 month of treatment—detect how well treatment is working in patients with skin cancer.

During the study, the researchers traced circulating tumor DNA (ctDNA) for the cancer gene BRAF, which plays a role in various types of melanoma. They found that a tumor’s BRAF mutation could be detected by the new blood test in 93% of the patients before treatment started. After 1 month of therapy, BRAF ctDNA levels were no longer detectable in the 40% of patients who had a positive clinical outcome after targeted therapy.

Read the full release.

Related Videos
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Kimberly Westrich, MA
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Ben Jones, McKesson/Us Oncology
Kathy Oubre, MS, Pontchartrain Cancer Center
Jonathan E. Levitt, Esq, Frier Levitt, LLC
Judy Alberto, MHA, RPh, BCOP, Community Oncology Alliance
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.